Nat. Volatiles & Essent. Oils, 2021; 8(4): 6426-6436

Compliance And Assurance Of Complete Manufacturing Of Tablets Following Ich Q10

Raj Kumar Singh[1], Prashant Nayak[1*], Bharath Raj K C[2], Prasanna Shama Khandige[3], Sivaa Arumugam R[4], Sindhu K[4], Raman Rajeshkumar[4]

[1]Department of Pharmaceutics, NGSM Institute of Pharmaceutical Sciences, NITTE (Deemed to be University), Mangaluru, Karnataka, 575018, India.

[2]Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, NITTE (Deemed to be University), Mangaluru, Karnataka, 575018, India.

[3]Department of Pharmacology, NGSM Institute of Pharmaceutical Sciences, NITTE (Deemed to be University), Mangaluru, Karnataka, 575018, India.

[4]Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India

Email: prashantn2001@nitte.edu.in

ABSTRACT

In the pharmaceutical sector, quality assurance ensures that the treatment given to the patient is both safe, effective and of higher quality. A variety of management and technical quality-control tasks, such as evaluating pharmaceutical product paperwork, executing, or monitoring product performance and analysing quality-control laboratory testing, are used to ensure product quality. Selecting a dependable supplier, drafting contract conditions, Managerial operations include things like keeping track of supplier performance and running inspection trials across the distribution network. Compliance Services ensures that the labs are compliant with international regulations. It will have a thorough, automated approach to investigation, documentation, and agreement by assuring with the supplier and agreeing the protocols under a single Universal Operational Qualification framework, streamlining processes across all main models of the pharmaceutical sector. In the pharmaceutical industry, tablet dosage forms should adhere to the ICH Q10 criteria. The models and statistical methodologies should meet the guidelines' requirements. Observation should be carried out throughout the tablet dosage form's life cycle.

Keywords: Quality Management System, Process performance, Change Management System

Introduction

The primary goal of pharmaceutical dose forms is to achieve the expected therapeutic effect of the medicine. Several components, such as physical and chemical stability, as well as appropriate microbial decontamination foresight, are necessary to maintain item quality. The crude ingredients and equipment determine the quality of pharmaceutical medication items. A medicinal dosage form, on the other hand, is a potent object whose colour, consistency, weight, and synthetic personality

can change between creation and final use. If packaging and storage are not done properly, upon reception, a pharmaceutical product that passes all research centre testing may become obsolete within a few months. (Lieberman 1990)

The International Organization for Standardization (ISO) quality concept is based on good manufacturing practice (GMP) standards and recommendations, and ICH Q10 has a number of models, one of which is a wide model for a successful pharmaceutical quality system.(FDA 2009)

GMP stands for Good Manufacturing Practices, and it assures that products are manufactured and regulated consistently to fulfil quality standards that are adequate for their intended application. GMP is primarily intended to reduce the risk associated with pharmaceutical production. Cross-contamination (particularly with unexpected contaminants) and mix-ups are the two main categories of such dangers (for example, false labelling).

The 10 golden rules of GMP

1. Get the facility design right from the start
2. Validate processes
3. Write good procedures and follow them
4. Identify who does what
5. Keep good records
6. Train and develop staff
7. Practice good hygiene
8. Maintain facilities and equipment
9. Build quality into the whole product lifecycle
10. Perform regular audits(FDA 2009, World health organization2007)

The pharmaceutical quality system, which is based on the ICHQ10 model, has standards in place to aid pharmaceutical firms by laying out a model for an effective quality management system for the drug business. [Pandey P 2018]

Drug industry is among the most astringently regulated producing divisions. Quality management system influences a final quality of the completed item. The idea of the current pharmaceutical quality management system depends on a globally orchestrated direction ICH Q10 which is created by the International Council for Harmonization of Technical Requirements for Registration of

Pharmaceuticals for Human Use and in conclusive stages for selection by the administrative the European Union's, Japan's, and the United States' assortments. This quality management system is based on scientific and risk-based techniques and can be used at many stages of the product life cycle. It integrates the essential quality concepts of the International Organization for Standardization (ISO). The ICH Q10 guidelines assist with advancement and continuous improvement in a non-mandatory manner, as well as serving as a link between drug development and manufacturing activities.(FDA 2009, Pandey P 2018)

The characteristic of management function that regulates and implements the "Quality policy" is well-defined as quality management. i.e. an organization's entire goal and direction in terms of quality, as expressed and authorised by top management. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) aids to produce homogeneity in the regulatory bodies and pharmaceutical industry to discuss scientific characteristics of drug registration and approval. International harmonized guidelines ICH Q10 benefits the Quality assurance department in a pharmaceutical industry to ensure that the finished goods are compliance to quality and customer satisfaction. It also implements the existing pharmaceutical quality management system for human drug registration. ICH is mainly focused on achieving greater harmonization worldwide to ensure the quality, safety and effectiveness of medicines. Key success of this process is the commitment of the ICH regulators to implement the Quality, Safety and Efficacy of marketed drug products. All the above guidelines serve as an actual quality management system for the pharmaceutical industry. The International Conference on Harmonization (ICH) Q10 presents a comprehensive model for a successful pharmaceutical quality system that directs and controls a manufacturer's ability to manage quality.(FDA 2009, Raghavendra D 2017, Priede J 2012)

Methods:

Quality Risk Management

A systematic technique of assessing, regulating, communicating, and reviewing threats to product quality is known as quality risk management. It has the ability to be employed both in a proactive and introspective manner. A good risk management strategy should ensure the following:(Chavda PV 2015)

- The threat to quality is assessed using scientific data, procedural expertise, and, lastly, the patient and client's certainty.

- The amount of effort, custom, and paperwork that leaders put into quality risk management is proportional to the level of threat.
- ICHQ9 pointed to the entire quality risk management, board involvement, and joining in to the product quality. (Chavda PV 2015, Bhattacharya J 2015)

QRM is made up of three primary components that work together to form a continuous improvement cycle.

- Risk Assessment
- Risk Control
- Risk Review(Bhattacharya J 2015)

RISK ASSESSMENT

The identification of dangers, as well as the evaluation and assessment of hazards associated with openness to such risks, are all part of the risk assessment process. The accompanying exercises are included in the risk assessment.(Bhattacharya J 2015)

- ✓ Identification of Hazards: In view of clear-cut cycle portrayal and satisfactory wellsprings of data (for example historical data, description of the possible consequences) recognize potential dangers, only "What may turn out badly?”
- ✓ Risk Analysis: Evaluations the danger related with the distinguished risk/s. It is the way toward connecting the likelihood of event and seriousness of damages.
- ✓ Risk Evaluation: An interaction which looks at the recognized and analysed risk against given risk standards. (Reddy Vijayakumar V 2014)

RISK CONTROL

Risk Control is a dynamic cycle that reduces the risk to a manageable level. It incorporates:

- ✓ Risk reduction: When a risk exceeds a certain level (inadequate) in terms of seriousness and possibility of injury, it is relieved or eliminated.
- ✓ Risk acceptance: Is it better to appear aloof when there are no lingering threats, or is it better to recognise the residual risk.(Bhattacharya J 2015,Reddy Vijayakumar V 2014)

RISK REVIEW

The viability of the risk management strategy should be examined on a regular basis based on substantial facts" (for example results of product review, inspections, audits, change control). Risk review is a core QMS action that is linked to the overall lifecycle and improvement process. (Chavda PV 2015, Reddy Vijayakumar V 2014)

Fig.1: Overview of a typical Quality Risk Management process



PHARMACEUTICAL DEVIATION

The deviation management system is dependable to guarantee any deviations from the composed systems are accounted for promptly, the appraisal of seriousness and recognizable proof of suitable CAPAs.(Eissa ME 2018)

The sec 211.100 of Code of Federal Regulations (CFR) states that; composed manufacturing and process control will be used to ensure that the medicine products have the identity, strength, quality, and purity that they have or are supposed to have. The quality control unit will examine and support these written procedures, including any amendments, after they have been created, reviewed, and endorsed by the appropriate authoritative units.(Priede J 2012)

DEVIATION CATEGORIZATION

As a fundamental necessity, personnel are relied upon to be ready and mindful of potential changes in the current procedures and to obviously realize how to deal with as indicated by GMP prerequisites. The utilization of a decision tree serves to at first screen the change dependent on their danger and effect on the product quality.(WHO 2021)

Minor Deviations

If a deviation does not affect any quality credits, a basic process parameter, or basic process or control equipment or instrument, it is classified as minor and regarded as such by the appropriate system.

Major Deviations

A deviation is deemed a major deviation when it impacts a quality characteristic, a process parameter, equipment, or instrument that is vital to the process or control.

Critical Deviations

The deviation is regarded crucial when it affects a quality property, a crucial process parameter, critical equipment or instrument for process or control, and the effect on patients, including dangerous circumstances.(Eissa ME 2018)(who 2021)

Change Control

Change management is regarded as the most fundamental component of a pharmaceutical company's quality management system. Absence of a framework to control the change winds up in making a gigantic risk of non-compliance to the final product. Drug organizations should control any progressions to set up measures and should be recorded, checked on, sway got to and supported by the Quality Assurance unit. Change control is "An interaction that guarantees the changes to material, methods, equipment and software are properly documented, validated, approved and traceable." (Ali H 2012)The EU GMP rule characterizes change control as "A conventional framework by which qualified delegates of fitting orders survey proposed or real changes that may influence the validated status of facilities, systems, equipment or processes. The plan is to decide the requirement for activity that would guarantee and report that the framework is kept up in a validated state."(Huma Ali 2012)(Lokesh MS 2015)

OOS (Out of Specification)

Out of specification results are characterised as outcomes from in-process or finished product testing that fall outside of predetermined constraints as mentioned in compendia, the drug master file, or the drug application. OOS can be caused by flaws in the product manufacturing process, flaws in the testing method, or failure of analytical equipment. When an OOS occurs, it is necessary to do a root cause analysis to determine the cause. There are assignable and non-assignable reasons for OOS. The limitations are called out of specifications when they are not within the prescribed limits. The analyst must contact the QC manager if an OOS occurs. Senior management will then ask for an OOS form to be sent to the analyst by QA. The designated personnel must classify the OOS as

assignable or non-assignable. A unique identification number will be assigned to each out-of-specification item.(Kuselman I 2012)

E.g.: OOS/RM-001/2020.Were, OOS –out of specification, RM –raw material (department), 001 –OOS for that year, 2020 –Year.(Kuselman I 2012)(Guidance for Industry 2021)

CORRECTIVE ACTION AND PREVENTIVE ACTION (CAPA)

Corrective and preventative action (CAPA) is an important management strategy that should be used by every pharmaceutical quality system. CAPA is a thorough technique that involves activities targeted at rectifying (correction), preventing recurrence (corrective action), and removing the source of possibly nonconforming goods and other quality issues (Preventive action).The Corrective action help to take out the reasons for a distinguished resistance or other unwanted circumstance and ought to take out the repeat of the issues. Though the preventive action is to dispose of the reason for an expected dissention or other bothersome likely circumstance.(Raj A 2016) (Abhishek R 2016)

Results

Table 1: Trending of primary root causes

Primary root cause	Number of events	Percentage
Man power	132	45%
Machine	80	27%
Method	45	16%
Material	28	9%
Measurement	10	3%
Total	**295**	**100%**

Table 2: Overview of total no. of deviations (before and after AQA) for the year 2020-21

Deviation	No. of Deviations	Percentage deviation
Deviation before AQA	52	66%
Deviation After AQA	27	34%
Total no. of deviation	79	100 %

Table 3: Overview of total no. of change control (before & after AQA) for the year 2020-21

Change control	No. of Change control	Percentage
Change control before AQA	49	42%
Change control After AQA	67	58%
Total no. of Change control	116	100 %

Table 4: Overview of total no. of OOS (before & after AQA) for the year 2020-21

Out of specification (OOS)	No. of Change control	Percentage
OOS before AQA	30	38%
OOS After AQA	48	62%
Total no. of OSS	78	100 %

Table 5: Overview of Corrective and Preventive actions (CAPAs) for the year of 2020-21

TYPE OF ACTION	No. OF CAPAs	PERCENTAGE
CAPAs involved redesign and redevelopment of process	15	58%
CAPSs involved retraining of personnel	11	42%
Total no. of CAPAs identified	26	100%

Discussion

Root Cause

Manpower is revealed to be the potential root cause (45 percent) among the 5Ms in root cause analysis. Machine, method, material, and measurements account for 27%, 16%, 9%, and 3% of the total, respectively. Each of the 5Ms has its own trending of sub-causes. Dilution error has been identified as a possible root cause among the manpower root causes, along with contamination, improper mixing, and instrument setup/use, improper saturation of filter paper, glassware selection error, and improper solution storage. The aforesaid sub-causes require the identification and execution of CAPA, Which can only be done by examining the analysts involved in these occurrences, because they are caused by manpower? As a corrective and preventative step, the analysts'

qualifications and training records will be evaluated, and a re-training plan based on applicable SOPs will be developed.

Deviations

From the sample, 79 deviations from the year 2020-21 were chosen. There were 52 deviations before the AQA review and 27 deviations after the AQA review, for a total of 66 percent and 34 percent before and after AQA, respectively. Following the review, the majority of the problems were discovered in calculation error, which tends to increase the number of deviations.

Change control

Following AQA's evaluation, the total number of change controls issued was 116, with an increase in the number of change controls after AQA's evaluation, i.e. 4percent before AQA and 58 percent after AQA. All of this is either documented in an electronic format or saved on paper Also, make sure that system softwareis intended to keep up with changing regulations, especially if new features are being implemented .

Out of specification

The overall number of OOS was 78, with an increase in the number of OOS following AQA's assessment, i.e., 38 percent before AQA and 62 percent after AQA, where OOS findings were disregarded without adequate reasons.

CAPA

In the 2020-21 fiscal year, the same case study pattern was used to identify Corrective and Preventive Actions (CAPA). A key sign of a high-quality culture has been found as a comprehensive Corrective and Preventive Action programme. Continual improvement is based on preventing the occurrence of a detected nonconformity or other undesirable circumstance in the first place (preventive action) or recurrence (corrective action).

Conclusion

Systems and processes must be assessed and controlled to remain regulatory compliance and to assure the cost-effective continuity of product supply. Accurate quality measures and continuous quality improvement are important tools in this setting.

Only measure what adds value to quality in the most efficient way; a strong quality metrics system promotes both industrial profitability and GMP compliance, and it prevents overproduction of metrics. The pharmaceutical sector can maintain a high-quality standard and decrease non-conformance by using a metric system that is suited for purpose. To achieve this, the industry must

come together in courses like this to learn and discuss how to establish a higher-quality system based on smart quality indicators.

Every organisation must understand how to effectively utilise quality measurements in order to solve quality-related issues.

Risks must be reviewed and handled in order to be regulatory compliance and to assure the quality, safety, and efficacy of the products. Accurate Risk Assessment, Risk Control, Risk Mitigation, and Continuous Quality Improvement are all important considerations in this setting.

High-quality in the pharmaceutical sector, risk management tools are employed to improve quality. The primary goal of QRM is to assure patient safety and increase product quality. When QRM is carried out effectively, it aids in the improvement of product quality. They will benefit from ongoing improvement in operational performance as well as GMP compliance, and they are critical for business and product supply continuity.

Implementing a high-quality risk management system only measure what adds value to quality in the most efficient way; the quality system promotes both industrial profitability and GMP compliance, and it prevents overproduction of metrics

References:

1. Lieberman, H.(1990) Pharmaceutical dosage forms: tablets. 2nd ed. New York: Dekker
2. FDA.(2009) Guidance for Industry Q10 Pharmaceutical Quality System. U.S. Department of Health and Human Services Food and Drug Administration. p. 1-19.
3. Quality assurance of pharmaceuticals. (2007)2nd ed. Geneva: World health organization
4. Pandey P, Anju G.(2018) Quality Management System in Drug Industry: A Review. Biomed J Sci & Tech Res. 2(1).
5. Raghavendra D, Chauhan R, Mallikarjuna T. (2017)Studying Strategies for Implementing Quality Culture in Pharmaceutical Organizations. Int J Pharm Qual Assur. 8(4), 57-67.
6. PriedeJ.(2012) Implementation of Quality Management System ISO 9001 in the World and its Strategic Necessity. Procedia - Social and Behavioral Sciences; 58, 1466-75.
7. Chavda PV, Maru S, Patel B.(2015) How Quality Risk Management is Useful for Pharmaceuticals. Glo Res J Sci Natu. 1(1), 10-13.
8. Bhattacharya J, Pharm M, Phil M.(2015) Quality Risk Management–Understanding and control the risk in pharmaceutical manufacturing industry. International Journal of Pharmaceutical Science Invention. Jan. 4(1), 29-41.
9. Reddy Vijayakumar V, Kashyap U, Raghunandan H, Gupta N.(2014) Quality Risk Management in Pharmaceutical Industry: A Review. Int J Pharm Tech Res. 6(3), 908-914.

10. Eissa ME, Abid AM.(2018) Application of statistical process control for spotting compliance to good pharmaceutical practice. Braz. J. Pharm. 54(2), 17499.
11. Deviation Handling and Quality Risk Management, World Health Organization (WHO)(2021), Geneva, Switzerland, 2013. Available from: http://www.who.int /immunization_standards / vaccine _quality /risk_july_2013.pdf?ua=1(Last Accessed on 22 April 2021).
12. Ali H, Gonjare N, D'souza M.(2012) Change Management in Pharmaceuticals: The most critical element of Quality Management System. Journal of Pharmacy Research.; 5(7),3706-8.
13. Huma Ali, Gonjare N, D Souza M.(2012) Change Management in Pharmaceuticals: The Most Critical Element of Quality Management System. J Pharm Res. 5(7), 3706-3708.
14. Lokesh MS, Vishal GN.(2015) Quality management system in change control at industry level: An overview. Int J Pharm Pharm Sci. 7(5), 13-9.
15. Kuselman I, Pennecchi F, Burns C, and Fajgelj A, de Zorzi P.(2012july) IUPAC /CITAC Guide: Investigating out-of-specification test results of chemical composition based on metrological concepts (IUPAC Technical Report). Pure and Applied Chemistry. 84(9), 1939-71.
16. Guidance for Industry, (2021) Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. https://www.fda.gov/downloads/drugs/guidances/ucm070287.pdf.(Last accessed on 29 April 2021).
17. Raj A. (2016)A review on corrective action and preventive action (CAPA). Afr J Pharma Pharmacol.10(1), 1-6.
18. Abhishek R.(2016) A Review on Corrective Action and Preventive Action (CAPA). Afr J Pharm Pharmacol.10 (1), 1-6.